tradingkey.logo

Revvity Inc

RVTY

84.000USD

+1.130+1.36%
Close 09/15, 16:00ETQuotes delayed by 15 min
9.77BMarket Cap
34.26P/E TTM

Revvity Inc

84.000

+1.130+1.36%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated2025-09-15

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
9 / 207
Overall Ranking
91 / 4724
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 20 analysts
Buy
Current Rating
120.359
Target Price
+45.24%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Revvity, Inc. is a provider of health science solutions, technologies, and services, which delivers workflows from discovery to development, and diagnosis to cure. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The Life Sciences Segment applications include MicroBeta, The MuviCyte live-cell imaging system, The Signals Image Artist, The VICTOR Nivo multimode plate reader benchtop system, The EnSight multimode plate reader benchtop system, BioLegend LEGENDplex bead-based reagents, and The Quantum GX2 system. Its Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. It offers instruments, reagents, assay platforms and software to hospitals, and medical labs. It is focused on reproductive health, immunodiagnostics, and emerging market diagnostics.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 12.14%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 12.14%.
Fairly Valued
The company’s latest PE is 35.70, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 113.79M shares, decreasing 5.83% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 14.03M shares of this stock.

Financial Health

Currency: USD Updated2025-09-15

The company's current financial score is 8.27, which is higher than the Healthcare Equipment & Supplies industry's average of 7.15. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 664.76M, representing a year-over-year increase of 2.28%, while its net profit experienced a year-over-year increase of 62.37%.

Score

Industry at a Glance

Previous score
8.27
Change
0.51

Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

9.01

Operational Efficiency

8.10

Growth Potential

7.49

Shareholder Returns

9.31

Company Valuation

Currency: USD Updated2025-09-15

The company’s current valuation score is 4.80, which is higher than the Healthcare Equipment & Supplies industry's average of 2.15. Its current P/E ratio is 37.66, which is 38.36% below the recent high of 52.10 and 48.71% above the recent low of 19.31.

Score

Industry at a Glance

Previous score
5.27
Change
-0.01

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 9/207
No Data

Earnings Forecast

Currency: USD Updated2025-09-15

The company’s current earnings forecast score is 7.60, which is lower than the Healthcare Equipment & Supplies industry's average of 7.66. The average price target for Revvity Inc is 115.00, with a high of 185.00 and a low of 90.00.

Score

Industry at a Glance

Previous score
7.60
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 20 analysts
Buy
Current Rating
120.359
Target Price
+45.24%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

94
Total
4
Median
7
Average
Company name
Ratings
Analysts
Revvity Inc
RVTY
20
Boston Scientific Corp
BSX
36
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
34
Veeva Systems Inc
VEEV
32
Thermo Fisher Scientific Inc
TMO
31
1
2
3
...
19

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated2025-09-15

The company’s current price momentum score is 6.77, which is lower than the Healthcare Equipment & Supplies industry's average of 7.47. Sideways: Currently, the stock price is trading between the resistance level at 93.83 and the support level at 84.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.43
Change
-0.08

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(4)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.618
Sell
RSI(14)
42.310
Neutral
STOCH(KDJ)(9,3,3)
33.196
Neutral
ATR(14)
2.886
High Vlolatility
CCI(14)
-88.346
Neutral
Williams %R
76.365
Sell
TRIX(12,20)
-0.318
Sell
StochRSI(14)
73.914
Neutral
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
84.018
Sell
MA10
84.994
Sell
MA20
87.894
Sell
MA50
91.379
Sell
MA100
92.676
Sell
MA200
102.479
Sell

Institutional Confidence

Currency: USD Updated2025-09-15

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. The latest institutional shareholding proportion is 98.03%, representing a quarter-over-quarter decrease of 1.80%. The largest institutional shareholder is The Vanguard, holding a total of 14.03M shares, representing 12.09% of shares outstanding, with 3.34% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
T. Rowe Price Investment Management, Inc.
22.52M
+8.45%
The Vanguard Group, Inc.
Star Investors
14.33M
+0.65%
T. Rowe Price Associates, Inc.
Star Investors
9.39M
+25.90%
Janus Henderson Investors
5.99M
-5.73%
EdgePoint Investment Group Inc.
Star Investors
5.36M
+32.10%
BlackRock Institutional Trust Company, N.A.
6.07M
+0.99%
State Street Global Advisors (US)
5.17M
+0.03%
Geode Capital Management, L.L.C.
2.99M
+3.18%
Capital Research Global Investors
2.84M
-5.09%
Invesco Capital Management LLC
Star Investors
1.52M
+0.80%
1
2

Risk Assessment

Currency: USD Updated2025-09-15

The company's beta value is 0.95. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
4.82
Change
0
Beta vs S&P 500 index
0.99
VaR
+3.11%
240-Day Maximum Drawdown
+35.42%
240-Day Volatility
+38.17%
Return
Best Daily Return
60 days
+5.96%
120 days
+10.40%
5 years
+10.40%
Worst Daily Return
60 days
-8.32%
120 days
-8.32%
5 years
-16.13%
Sharpe Ratio
60 days
-1.35
120 days
-1.00
5 years
-0.13
Risk Assessment
Maximum Drawdown
240 days
+35.42%
3 years
+44.52%
5 years
+59.18%
Return-to-Drawdown Ratio
240 days
-0.97
3 years
-0.29
5 years
-0.13
Skewness
240 days
+0.22
3 years
-0.21
5 years
-0.13
Volatility
Realised Volatility
240 days
+38.17%
5 years
+34.39%
Standardised True Range
240 days
+4.08%
5 years
+4.55%
Downside Risk-Adjusted Return
120 days
-153.35%
240 days
-153.35%
Maximum Daily Upside Volatility
60 days
+33.23%
Maximum Daily Downside Volatility
60 days
+31.03%
Liquidity
Average Turnover Rate
60 days
+1.04%
120 days
+1.06%
5 years
--
Turnover Deviation
20 days
+18.56%
60 days
+31.65%
120 days
+34.53%

Peer Comparison

Healthcare Equipment & Supplies
Revvity Inc
Revvity Inc
RVTY
7.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
7.98 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
WST
7.79 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
7.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
7.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Merit Medical Systems Inc
Merit Medical Systems Inc
MMSI
7.49 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI